

Head and Neck Cancer Therapeutics - A Global Market Overview

Market Report | 2024-11-05 | 301 pages | Industry Experts

AVAILABLE LICENSES:

- Single user licence (PDF) \$4500.00
- Enterprise Electronic (PDF) \$7200.00

Report description:

Head and Neck Cancer Therapeutics Market Trends and Outlook

Head and neck cancer encompasses a diverse group of malignancies that develop in specific regions of the head and neck, including the lips, oral cavity (mouth), nasal cavity, pharynx (throat), larynx (voice box), salivary glands, and paranasal sinuses. These cancers are squamous cell carcinomas that usually begin from the flat cells lining the mucosal surfaces of these regions. Risk factors contributing to the development of these cancers include tobacco use (both smoking and chewing), excessive alcohol consumption, and infection with human papillomavirus (HPV). Identifying the condition can be challenging due to mild symptoms that may mimic less severe ailments, such as persistent sores that do not heal, red or white patches in the mouth, an enduring sore throat, and hoarseness. Timely detection is crucial for effective treatment, which usually involves physical examinations, endoscopic assessments, imaging, and laboratory tests.

Therapies commonly employed for head and neck cancer include immunotherapy, which enhances the body's immune response to destroy cancer cells; targeted therapy, which uses medications to specifically inhibit molecules like the epidermal growth factor receptor (EGFR) that contribute to cancer progression; and chemotherapy, a traditional treatment that employs powerful drugs to kill or slow the growth of cancer cells. Treatment plans vary based on factors such as the cancer's location and stage, the patient's age, and overall health, underscoring the necessity for tailored approaches, as different cancer types respond uniquely to treatments. The global market for Head and Neck Cancer Therapeutics is estimated at US\$1.7 billion in 2024 and is anticipated to post a CAGR of 9.4% during the 2024-2030 analysis period and stand at a projected US\$3 billion by 2030.

head-and-neck-cancer-therapeutics-market

The head and neck cancer market is primarily driven by increased research and development, which leads to the approval of new drugs, particularly for immunotherapy, targeted therapy, and chemotherapy. Healthcare providers are developing effective treatment options for several types of head and neck cancers, as evidenced by FDA approvals for drugs like Cetuximab and Docetaxel. Market growth is also driven by the rising incidence of HPV infections and increased consumption of alcohol and tobacco, which contribute to the prevalence of head and neck cancers. Additionally, advancements in diagnostic techniques allow for earlier detection, thereby improving treatment outcomes and increasing demand. Nevertheless, the market faces challenges such as high treatment costs limiting access for low- and middle-income patients, as well as adverse side effects like neuropathy and fatigue. Treatment resistance, where cancer cells evade therapies, and lengthy regulatory approval processes further impede

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

market growth.

Head and Neck Cancer Therapeutics Regional Market Analysis

In 2024, North America led the global head and neck cancer therapeutics market, holding an estimated 46.8% market share. Growth in this region is attributed to its advanced healthcare infrastructure, strong awareness of the disease, substantial investments in research and development, and favorable reimbursement policies. The region's dominant position is supported by its robust healthcare system and the high incidence of head and neck cancer associated with tobacco, alcohol, and HPV. Conversely, the Asia Pacific region is expected to witness substantial growth with a CAGR of 10.9% during the forecast period 2024-2030, driven by the increasing number of head and neck cancer cases due to alcohol and tobacco use, growing consumer awareness, and higher healthcare spending. Market expansion in this region is further stimulated by the improving healthcare infrastructure, aging population, and rising disposable incomes. Countries such as China and India are particularly affected by a high prevalence of cancer, influenced by lifestyle factors and government efforts to improve cancer care.

head-and-neck-cancer-therapeutics-market by region

Head and Neck Cancer Therapeutics Market Analysis by Drug Class

Programmed Cell Death (PD) Inhibitors dominate the head and neck cancer therapeutics market with an estimated share of 42.1% in 2024 and is projected to be the fastest-growing therapeutic class, with a CAGR of 10.5% during the analysis period 2024-2030. These inhibitors have shown promising results in improving survival rates and extending progression-free survival, especially in patients with advanced or recurrent cancer. Due to their effectiveness, there is increasing demand for both monotherapy and combination treatments. Current clinical trials are focused on improving treatment approaches, identifying relevant biomarkers, and exploring new combinations.

Head and Neck Cancer Therapeutics Market Analysis by Treatment Type

Immunotherapy is the largest market in the head and neck cancer therapeutics market, holding a share of 43.6% in 2024, and is projected to record the fastest CAGR of 10.7% during the analysis period 2024-2030. By utilizing the body's immune system to target cancer cells, immunotherapy presents promising treatment options for advanced or recurring head and neck cancers, with Pembrolizumab established as a primary therapy. Growth in this sector is expected due to increased patient awareness and the active involvement of the FDA and EMA in approving new formulations. Targeted therapy held the second-largest market share at 22% in 2024, concentrating on specific molecular changes in tumors by interrupting critical signaling pathways. The active participation of companies and healthcare organizations further bolsters the expansion of targeted therapies.

Head and Neck Cancer Therapeutics Market Analysis by Route of Administration

The injectable segment dominated the head and neck cancer therapeutics market in 2024, with a 67.4% share. This dominance is attributed to the effectiveness of various cancer medications, such as chemotherapy and immunotherapy, administered intravenously or through injectables to ensure better absorption and efficacy. Injectable drugs like Cisplatin are notable for their controlled delivery and improved formulations, enhancing treatment efficacy. Conversely, oral administration is anticipated to be the fastest-growing segment, with a CAGR of 10.4% during the forecast period 2024-2030, driven by advancements in oral chemotherapy formulations and patient preferences for convenient at-home treatment options. Oral medications provide flexible treatment schedules, reduce clinic visits, and contribute to personalized head and neck cancer treatment strategies, improving patients' overall quality of life.

head-and-neck-cancer-therapeutics-market by administration route

Head and Neck Cancer Therapeutics Market Analysis by End-User

In 2024, hospitals dominate the head and neck cancer therapeutics end-user market, holding an estimated share of 49.1% due to their well-equipped infrastructure and advanced disease diagnosis capabilities. On the other hand, the Ambulatory Surgical Centers (ASCs) segment is anticipated to register the fastest CAGR of 10.9% during the analysis period from 2024 to 2030, propelled by the increasing demand for cost-effective outpatient surgical treatments and technological progress enabling complex

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

procedures in ASCs. Additionally, this growth is further driven by the rising prevalence of the disease and the necessity for faster treatment options.

Head and Neck Cancer Therapeutics Market Report Scope

This global report on Head and Neck Cancer Therapeutics analyzes the market based on drug class, treatment type, route of administration, and end-users. In addition to providing profiles of major companies operating in this space, the latest corporate and industrial developments have been covered to offer a clear panorama of how and where the market is progressing.

Key Metrics

Historical Period: 2021-2023

Base Year: 2023

Forecast Period: 2024-2030

Units: Value market in US\$

Companies Mentioned: 10+

Head and Neck Cancer Therapeutics Market by Geographic Region

North America (The United States, Canada, and Mexico)

Europe (Germany, France, United Kingdom, Italy, Spain, and Rest of Europe)

Asia-Pacific (Japan, China, India, South Korea, and Rest of Asia-Pacific)

South America (Brazil, Argentina, and Rest of South America)

Rest of World

Head and Neck Cancer Therapeutics Market by Drug Class

Programmed Cell Death (PD) Inhibitors

Microtubule Inhibitors

Epidermal Growth Factor Receptor (EGFR) Inhibitors

Head and Neck Cancer Therapeutics Market by Treatment Type

Immunotherapy

Targeted Therapy

Chemotherapy

Radiation Therapy

Surgery

Head and Neck Cancer Therapeutics Market by Route of Administration

Injectable

Oral

Head and Neck Cancer Therapeutics Market by End-User

Hospitals

Specialty Clinics

Ambulatory Surgical Centers (ASCs)

Table of Contents:

PART A: GLOBAL MARKET PERSPECTIVE

1. INTRODUCTION

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- Product Outline
- Head and Neck Cancer Therapeutics Defined
- Head and Neck Cancer Therapeutic Drug Classes
 - o□Programmed Cell Death (PD) Inhibitors
 - o□Microtubule Inhibitors
 - o□Epidermal Growth Factor Receptor (EGFR) Inhibitors
- Head and Neck Cancer Therapeutic Treatment Types
 - o□Immunotherapy
 - o□Targeted Therapy
 - o□Chemotherapy
 - o□Radiation Therapy
 - o□Surgery
- Head and Neck Cancer Therapeutic Route of Administration
 - o□Injectable
 - o□Oral
- Head and Neck Cancer Therapeutic End-Users
 - o□Hospitals
 - o□Specialty Clinics
 - o□Ambulatory Surgical Centers (ASCs)
- 2. Key Market Trends
- 3. Key Global Players
 - AbbVie Inc.
 - AstraZeneca plc
 - Bayer AG
 - Bristol-Myers Squibb Company
 - Eli Lilly and Company
 - F. Hoffmann-La Roche AG
 - Merck & Co., Inc.
 - Novartis AG
 - Pfizer Inc.
 - Sanofi S.A.
 - Takeda Pharmaceutical Company Limited
 - Teva Pharmaceutical Industries Ltd.
- 4. Key Business & Product Trends
- 5. Global Market Overview
 - Global Head and Neck Cancer Therapeutics Market Overview by Drug Class
 - o□Head and Neck Cancer Therapeutics Drug Class Market Overview by Global Region
 - Programmed Cell Death (PD) Inhibitors
 - Microtubule Inhibitors
 - Epidermal Growth Factor Receptor (EGFR) Inhibitors
 - Global Head and Neck Cancer Therapeutics Market Overview by Treatment Type
 - o□Head and Neck Cancer Therapeutics Treatment Type Market Overview by Global Region
 - Immunotherapy
 - Targeted Therapy
 - Chemotherapy
 - Radiation Therapy
 - Surgery

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- Global Head and Neck Cancer Therapeutics Market Overview by Route of Administration
- o□Head and Neck Cancer Therapeutics Route of Administration Market Overview by Global Region
- Injectable
- Oral
- Global Head and Neck Cancer Therapeutics Market Overview by End-User
- o□Head and Neck Cancer Therapeutics End-User Market Overview by Global Region
- Hospitals
- Specialty Clinics
- Ambulatory Surgical Centers (ASCs)?

PART B: REGIONAL MARKET PERSPECTIVE

Global Head and Neck Cancer Therapeutics Market Overview by Geographic Region

REGIONAL MARKET OVERVIEW

6. North America

- North American Head and Neck Cancer Therapeutics Market Overview by Geographic Region
- North American Head and Neck Cancer Therapeutics Market Overview by Drug Class
- North American Head and Neck Cancer Therapeutics Market Overview by Treatment Type
- North American Head and Neck Cancer Therapeutics Market Overview by Route of Administration
- North American Head and Neck Cancer Therapeutics Market Overview by End-User
- Country-wise Analysis of North American Head and Neck Cancer Therapeutics Market
- o□The United States
- United States Head and Neck Cancer Therapeutics Market Overview by Drug Class
- United States Head and Neck Cancer Therapeutics Market Overview by Treatment Type
- United States Head and Neck Cancer Therapeutics Market Overview by Route of Administration
- United States Head and Neck Cancer Therapeutics Market Overview by End-User
- o□Canada
- Canadian Head and Neck Cancer Therapeutics Market Overview by Drug Class
- Canadian Head and Neck Cancer Therapeutics Market Overview by Treatment Type
- Canadian Head and Neck Cancer Therapeutics Market Overview by Route of Administration
- Canadian Head and Neck Cancer Therapeutics Market Overview by End-User
- o□Mexico
- Mexican Head and Neck Cancer Therapeutics Market Overview by Drug Class
- Mexican Head and Neck Cancer Therapeutics Market Overview by Treatment Type
- Mexican Head and Neck Cancer Therapeutics Market Overview by Route of Administration
- Mexican Head and Neck Cancer Therapeutics Market Overview by End-User

7. Europe

- European Head and Neck Cancer Therapeutics Market Overview by Geographic Region
- European Head and Neck Cancer Therapeutics Market Overview by Drug Class
- European Head and Neck Cancer Therapeutics Market Overview by Treatment Type
- European Head and Neck Cancer Therapeutics Market Overview by Route of Administration
- European Head and Neck Cancer Therapeutics Market Overview by End-User
- Country-wise Analysis of European Head and Neck Cancer Therapeutics Market
- o□Germany
- German Head and Neck Cancer Therapeutics Market Overview by Drug Class
- German Head and Neck Cancer Therapeutics Market Overview by Treatment Type
- German Head and Neck Cancer Therapeutics Market Overview by Route of Administration
- German Head and Neck Cancer Therapeutics Market Overview by End-User
- o□France

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- [] French Head and Neck Cancer Therapeutics Market Overview by Drug Class
- [] French Head and Neck Cancer Therapeutics Market Overview by Treatment Type
- [] French Head and Neck Cancer Therapeutics Market Overview by Route of Administration
- [] French Head and Neck Cancer Therapeutics Market Overview by End-User
- o [] The United Kingdom
 - [] United Kingdom Head and Neck Cancer Therapeutics Market Overview by Drug Class
 - [] United Kingdom Head and Neck Cancer Therapeutics Market Overview by Treatment Type
 - [] United Kingdom Head and Neck Cancer Therapeutics Market Overview by Route of Administration
 - [] United Kingdom Head and Neck Cancer Therapeutics Market Overview by End-User
- o [] Italy
 - [] Italian Head and Neck Cancer Therapeutics Market Overview by Drug Class
 - [] Italian Head and Neck Cancer Therapeutics Market Overview by Treatment Type
 - [] Italian Head and Neck Cancer Therapeutics Market Overview by Route of Administration
 - [] Italian Head and Neck Cancer Therapeutics Market Overview by End-User
- o [] Spain
 - [] Spanish Head and Neck Cancer Therapeutics Market Overview by Drug Class
 - [] Spanish Head and Neck Cancer Therapeutics Market Overview by Treatment Type
 - [] Spanish Head and Neck Cancer Therapeutics Market Overview by Route of Administration
 - [] Spanish Head and Neck Cancer Therapeutics Market Overview by End-User
- o [] Rest of Europe
 - [] Rest of Europe Head and Neck Cancer Therapeutics Market Overview by Drug Class
 - [] Rest of Europe Head and Neck Cancer Therapeutics Market Overview by Treatment Type
 - [] Rest of Europe Head and Neck Cancer Therapeutics Market Overview by Route of Administration
 - [] Rest of Europe Head and Neck Cancer Therapeutics Market Overview by End-User
- 8. Asia-Pacific
 - [] Asia-Pacific Head and Neck Cancer Therapeutics Market Overview by Geographic Region
 - [] Asia-Pacific Head and Neck Cancer Therapeutics Market Overview by Drug Class
 - [] Asia-Pacific Head and Neck Cancer Therapeutics Market Overview by Treatment Type
 - [] Asia-Pacific Head and Neck Cancer Therapeutics Market Overview by Route of Administration
 - [] Asia-Pacific Head and Neck Cancer Therapeutics Market Overview by End-User
 - [] Country-wise Analysis of Asia-Pacific Head and Neck Cancer Therapeutics Market
- o [] Japan
 - [] Japanese Head and Neck Cancer Therapeutics Market Overview by Drug Class
 - [] Japanese Head and Neck Cancer Therapeutics Market Overview by Treatment Type
 - [] Japanese Head and Neck Cancer Therapeutics Market Overview by Route of Administration
 - [] Japanese Head and Neck Cancer Therapeutics Market Overview by End-User
- o [] China
 - [] Chinese Head and Neck Cancer Therapeutics Market Overview by Drug Class
 - [] Chinese Head and Neck Cancer Therapeutics Market Overview by Treatment Type
 - [] Chinese Head and Neck Cancer Therapeutics Market Overview by Route of Administration
 - [] Chinese Head and Neck Cancer Therapeutics Market Overview by End-User
- o [] India
 - [] Indian Head and Neck Cancer Therapeutics Market Overview by Drug Class
 - [] Indian Head and Neck Cancer Therapeutics Market Overview by Treatment Type
 - [] Indian Head and Neck Cancer Therapeutics Market Overview by Route of Administration
 - [] Indian Head and Neck Cancer Therapeutics Market Overview by End-User
- o [] South Korea

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- South Korean Head and Neck Cancer Therapeutics Market Overview by Drug Class
- South Korean Head and Neck Cancer Therapeutics Market Overview by Treatment Type
- South Korean Head and Neck Cancer Therapeutics Market Overview by Route of Administration
- South Korean Head and Neck Cancer Therapeutics Market Overview by End-User
- o□Rest of Asia-Pacific
- Rest of Asia-Pacific Head and Neck Cancer Therapeutics Market Overview by Drug Class
- Rest of Asia-Pacific Head and Neck Cancer Therapeutics Market Overview by Treatment Type
- Rest of Asia-Pacific Head and Neck Cancer Therapeutics Market Overview by Route of Administration
- Rest of Asia-Pacific Head and Neck Cancer Therapeutics Market Overview by End-User

9. South America

- South American Head and Neck Cancer Therapeutics Market Overview by Geographic Region
- South American Head and Neck Cancer Therapeutics Market Overview by Drug Class
- South American Head and Neck Cancer Therapeutics Market Overview by Treatment Type
- South American Head and Neck Cancer Therapeutics Market Overview by Route of Administration
- South American Head and Neck Cancer Therapeutics Market Overview by End-User
- Country-wise Analysis of Asia-Pacific Head and Neck Cancer Therapeutics Market

o□Brazil

- Brazilian Head and Neck Cancer Therapeutics Market Overview by Drug Class
- Brazilian Head and Neck Cancer Therapeutics Market Overview by Treatment Type
- Brazilian Head and Neck Cancer Therapeutics Market Overview by Route of Administration
- Brazilian Head and Neck Cancer Therapeutics Market Overview by End-User

o□Argentina

- Argentine Head and Neck Cancer Therapeutics Market Overview by Drug Class
- Argentine Head and Neck Cancer Therapeutics Market Overview by Treatment Type
- Argentine Head and Neck Cancer Therapeutics Market Overview by Route of Administration
- Argentine Head and Neck Cancer Therapeutics Market Overview by End-User

o□Rest of South America

- Rest of South American Head and Neck Cancer Therapeutics Market Overview by Drug Class
- Rest of South American Head and Neck Cancer Therapeutics Market Overview by Treatment Type
- Rest of South American Head and Neck Cancer Therapeutics Market Overview by Route of Administration
- Rest of South American Head and Neck Cancer Therapeutics Market Overview by End-User

10. Rest of World

- Rest of World Head and Neck Cancer Therapeutics Market Overview by Drug Class
- Rest of World Head and Neck Cancer Therapeutics Market Overview by Treatment Type
- Rest of World Head and Neck Cancer Therapeutics Market Overview by Route of Administration
- Rest of World Head and Neck Cancer Therapeutics Market Overview by End-User

PART C: GUIDE TO THE INDUSTRY

PART D: ANNEXURE

1. RESEARCH METHODOLOGY

2. FEEDBACK

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Head and Neck Cancer Therapeutics - A Global Market Overview

Market Report | 2024-11-05 | 301 pages | Industry Experts

To place an Order with Scotts International:

- Print this form
- Complete the relevant blank fields and sign
- Send as a scanned email to support@scott's-international.com

ORDER FORM:

Select license	License	Price
	Single user licence (PDF)	\$4500.00
	Enterprise Electronic (PDF)	\$7200.00
		VAT
		Total

*Please circle the relevant license option. For any questions please contact support@scott's-international.com or 0048 603 394 346.

** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>
		Date	<input type="text" value="2026-02-23"/>
		Signature	<input type="text"/>

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scott's-international.com

www.scott's-international.com